


Behandlingsplaner

Early MTX step-up plan for active persistent oligoarticular JIA	2019
Forfattergruppe: prof. dr. med. Berit Flatø, NAKBUR, OUS i samarbeid med NAKBURs nasjonale faglige referansegruppe	
Dokumentet er godkjent av NAKBURs referansegruppe. Publisert første gang 2019.	



JADAS= Juvenile Arthritis Disease Activity Scale. MD= Physicians global assessment of disease activity.

Footnote 1: Adalimumab, etanercept (if no uveitis or IBD), golimumab, or infliximab (in line with the Norwegian LIS TNF BIO recommendations)

Footnote 2: If tried 2 anti TNFs, change mechanism to tocilizumab or abatacept

Consensus treatment plans, expert reviews, and the American College of Rheumatology (ACR) treatment plans

Referanser

1. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Martini A, Rabinovich CE, Ruperto N. *Arthritis Care Res (Hoboken)*. 2011 Apr;63(4):465-82
2. Methotrexate in juvenile idiopathic arthritis: towards tailor-made treatment. Calasan MB1, Wulffraat NM. *Expert Rev Clin Immunol*. 2014 Jul;10(7):843-54. doi: 10.1586/1744666X.2014.916617.
3. Consolaro A, Ruperto N, Bazzo A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. *Arthritis Rheum* 2009 May 15;61(5):658-66.